Serabelisib - ARTham Therapeutics
Alternative Names: ART-001; KP-001Latest Information Update: 09 Jun 2026
At a glance
- Originator ARTham Therapeutics
- Developer ARTham Therapeutics; Kaken Pharmaceutical
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Benzoxazoles; Cardiovascular therapies; Imidazoles; Ketones; Morpholines; Pyridines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Vascular malformations
Most Recent Events
- 15 May 2026 Preregistration for Vascular malformations (In adolescents, In children, In adults) in Japan (PO)
- 15 May 2026 Kaken Pharmaceutical files an regulatory application with the Ministry of Health, Labour and Welfare (MHLW) in Japan for vascular malformations
- 09 Feb 2026 Chemical structure information added.